Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OneSource Specialty Pharma Limited ( (IN:ONESOURCE) ) has issued an announcement.
OneSource Specialty Pharma Limited has notified the stock exchanges that it has published newspaper advertisements containing extracts of its unaudited financial results for the quarter ended 31 December 2025, in compliance with SEBI’s listing and disclosure regulations. The move underscores the company’s adherence to mandatory transparency and reporting standards for listed entities, ensuring that investors and other market participants have formal public access to its quarterly financial performance through widely circulated financial dailies.
More about OneSource Specialty Pharma Limited
OneSource Specialty Pharma Limited, formerly known as Stelis Biopharma Limited, operates in the specialty pharmaceutical and contract development and manufacturing (CDMO) space, providing pharma-related services from its corporate base in Bengaluru and registered office in Navi Mumbai, India. The company is listed on both BSE and NSE under the symbol ONESOURCE, reflecting its positioning in India’s listed pharmaceutical and specialty pharma services sector.
Average Trading Volume: 7,256
Technical Sentiment Signal: Strong Sell
Current Market Cap: 164.2B INR
For detailed information about ONESOURCE stock, go to TipRanks’ Stock Analysis page.